We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Microsaic Systems Plc | LSE:MSYS | London | Ordinary Share | GB00BMWC8365 | ORD GBP0.00001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 4.76% | 1.10 | 1.00 | 1.10 | 1.05 | 1.05 | 1.05 | 397,039 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 1.57M | -2.29M | -0.0128 | -0.82 | 1.88M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/12/2017 08:34 | more like 3.0p at this rate! Look at it go :o Edit: (Compared to 2.5) | redfox05 | |
13/12/2017 08:26 | 50p actually mate | colin12345678 | |
13/12/2017 08:24 | They were 40p! | miahkaysor | |
13/12/2017 08:22 | 2.5p next stop? | miahkaysor | |
13/12/2017 08:07 | Global Pharma agreement - Can't buy a bean - | tomboyb | |
29/11/2017 11:44 | For those of you that know Microsaic Systems already, we’ve commercialised our miniature technology which has historically been targeted at chemical and biological analysis but usually confined to the research laboratory, now what we’re doing is to take the mass spec into places that it usually doesn’t go which is into the manufacturing workflow. This is particularly important right now, we’re seeing an entirely new breed of drug being developed and that requires a very different approach to its design and manufacture by pharma companies and in particular, biopharma are very interested in enhancing their sensing and detection capabilities to drive what they call ‘critical process’ parameters of the biologic workflow and also critical quality attributes of the biologics themselves. So, to answer your question, what I’ve been busy doing is to ensure that we’re working with the global life science partners who are asking us to participate in this very exciting new area. | swizz | |
29/11/2017 11:07 | Movement!....GL S PYC here we come. | swizz | |
28/11/2017 17:20 | What a sorry state of affairs and the BOD should hang their heads in shame, that said when you look at PYC today and the way the market has reacted to their news, with Microsaic ticking a lot of similar boxes, MSYS may have another day in the spotlight,...GL S | swizz | |
08/11/2017 19:40 | The new CEO reaching out and long overdue, hopefully the start of a more engaging future for shareholders,....GL S | swizz | |
05/10/2017 21:32 | Finally some interest, I would not be surprised to see an MBO develop with Microsaic and them take the company private,...GL S | swizz | |
28/9/2017 14:26 | MSYS - Now in takeover territory,....GL S | swizz | |
28/9/2017 07:55 | £4M cash, Time for shareholders to become a bit more pro-active? .....GL S With circa £4m cash, £16m (RE) and value of IP, this needs shaking up IMHO. | swizz | |
26/4/2017 09:17 | Trouble is Chinese competition as it develops. Cheap. They can upset all sorts. | p1nkfish | |
26/4/2017 08:11 | RNS, Confirms the collaboration with SCPA and also confirms in my opinion a more dynamic sales approach to the wider market and various industry sectors that have a mass appeal for MS functionality, bodes well and are we seeing the early shoots of the business transformation, along with the much needed revenue generation,.....GL S Btw - Good to the company twitter stream becoming more active, another interesting snippet details GE, an enhanced collaboration with those guys would raise the pulse! | swizz | |
18/4/2017 14:10 | New product launch imminent by the looks of things,.....GL S Microsaic @Microsaic We've listened to customer feed-back to make even better instruments in the future.Stay tuned! #MassSpec #CompactAnalysis | swizz | |
17/4/2017 19:09 | Interesting to note Sciex are currently facing a challenging time, as a result of two recent catastrophic failures of the their MS systems, they have advised users of circa 2000 systems that they should be immediately shut down, hopefully Microsaic and their OEM partners will be on hand to assist,.....GL S hxxp://cen.acs.org/a | swizz | |
17/4/2017 18:26 | cb, I know the buyer, that aside, I think the takeover thought is a sound one and in all probability would be the best prospect for shareholders and I do wonder how much longer Parkwalk are going to sit on the sidelines, they are certainly well connected and a bit of shareholder activism, may just stimulate someone in to action, it would not be a huge surprise if Parkwalk are behind the latest more meaningful move towards Bio processing and hopefully this will finally be the catalyst to drive meaningful sales volume,...GL S | swizz | |
28/2/2017 21:40 | How do you know swizz? Two x 500k trades sure, but look at the slight price difference, they could easily be a buy and a sell. Have you any comments on my post above? Ta. | cyberbub | |
28/2/2017 21:32 | Someone is building a decent position,.....GL S | swizz | |
22/2/2017 20:46 | I noticed a flattening out of the chart, and a bit of a volume spike last month, which piqued my interest. This company looks to have interesting technology, cutting costs in an important and growing field. And it seems to have a number of worldwide distribution/sales channels. So why are its sales so pathetically small, year after year? They are making a 35% gross profit or thereabouts, so to cover cash burn of £4m per year (never mind make a profit) they need to have sales of over £10M... not £1M!! Surely if its sales have been predicted in its recent trading statement to be only 8% ahead of 2015, then it is going to make another massive loss in the year to Jan 31, 2017? And the £5M it raised last summer will only last it until the end of 2017 or early 2018 at latest? By the end of 2017 unless it has started making a profit (which seems quite unlikely, from the trading statement) then surely it's for the knacker's yard, or alternatively a low-ball takeover if the tech really is any good and the buyer thinks they can make a better job of sales? I am wondering whether the best prospect for shareholders here is in fact a takeover in 2017? If Microsaic have genuine patents on the technology then those could be worth something to a bigger fish. A global medical technology company could easily offer 10p per share, it would be chump-change for them and they could easily integrate sales into a much larger sales team and get better growth rates. Maybe even more than 10p per share could be achievable. I am just researching here, so any comments would be appreciated, especially about their patents. Thanks. | cyberbub | |
27/8/2016 11:12 | johnwall Many thanks - I do appreciate the risks of AIM but this co has been quiet for some time so it was disappointing that their latest RNS apart from providing the latest a/cs announced the placing. Also look at the share price graph above - some AIM companies SPs do head N on occasion. Then there is the tiny number of shares that MMs permit investors to buy/sell at the specified share price Any sells above that number are at well below published bid share price The company has hardly been informative in the previous RNS either. What was the following June RNS about? 20 June 2016 Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry instruments, announces that at its Annual General Meeting held on 20 June 2016 ("AGM"), ordinary resolutions 1 to 8 were passed. Resolution 9, a special resolution regarding disapplication of pre-emption rights, was withdrawn by the Directors prior to commencement of the AGM. Previously there had been much progress reported but yet another rights issue. Before that there had been a positive announcement that: Microsaic Systems plc (AIM: MSYS), the developer of miniaturised chip-based scientific instruments, announces an improved business performance in the six months to 31 December 2015. The Company sold seventeen 4000 MiD® units in H2 2015 versus six units in H1 2015. The Board anticipates that sales for H1 2016 will continue this positive trend. The Company is pleased to announce that it has also signed a new distributor agreement for the 4000 MiD®; details of which will be provided in the 2015 Annual Report. Then share options granted along the lines of: These share options were granted under the Microsaic Systems Enterprise Management Incentive Scheme with an exercise price of 23.5 pence per ordinary share, being the closing mid-market price of the Company's shares on 12 January 2016. The options granted to Mr Ramage will vest on 1 January 2017. Gave ordinary PIs imho grounds for assuming that by September 2016 the co's share price would not be at an all time low. Frankly a little more realism would have been more apt I sold half my holding at a loss and sadly am far from convinced that the other half will ever show blue - happy to be proved wrong of course. | maytrees | |
26/8/2016 16:28 | maytrees - yes, but this is AIM! On the plus side, at least 3 of the Directors are stumping up £25k each, and the rest £15k. No doubt they had to show willing in order to get the Placing away, but maybe £25k is more than just 'showing willing'? If my arithmetic is correct, following the Placing there'll be 181m shares in issue so at 5p the MCap is £9.05m and they'll have £7m in cash. So - IF the new strategy can get them some real commercial traction (unlike the old one) this might be a good point to get in at. | johnwall | |
26/8/2016 16:25 | RNS released midday on a Friday tells you something. If the Placing Resolution is not passed at the General Meeting or the Placing does not proceed for any reason, no further assurance can be given that the Company will be able to continue as a going concern. | ohisay | |
26/8/2016 16:13 | Pretty poor by the co imho johnwall | maytrees | |
26/8/2016 15:59 | So - placing of 108m shares at 5p - lucky for the sellers of a couple of weeks ago that there was so much excitement generated on Twitter. | johnwall |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions